Published Paper Details:

Abstract Pulmonary alveolar proteinosis (PAP) is a kind of Lung disease that the alveoli is filled with the Periodic Acid Schiff (PAS) and it has a Positive Proteinaceous material in lips. It is auto immune disease mostly affected by 90% of people. PAP is mainly affected by the Type-II Alveolar cells and alveolar macrophage and causes the abnormalities of Pulmonary Surfactant clearness. The Surfactant (Essential element inside the lungs that prevent the tiny air sac-Alveoli) accumulates within the alveoli due to increase production rather than decrease clearance. It blocks air entering into the alveoli and difficult to pass the oxygen into the blood result in Dyspnea and Hypoxemia. PAP causes some symptoms like a dypnea, cough, chest pain, feeling tired, fever, etc... Lessen exhaustion, coughing, and dyspnea. Take care of hypoxemia, or low blood oxygen. Take the lipoproteinaceous material out of the alveoli physically. Use GM-CSF for autoimmune PAP (aPAP) or treat related disorders (secondary PAP). Prevent respiratory failure and control infections. Methodology: PAP was diagnosed by the chest X-ray, CT scan and confirmed by using the staining of Broncho alveolar lavage fluid(BALF).It can be Evaluated at some conditions like Pulmonary function test, Radiological evaluation, GM-CSF(Granulocyte macrophage colony stimulating factor) signalling test etc.. It has no genetic test to diagnose the Autoimmune PAP. Results: Therapeutic decisions are largely based on disease severity and type of PAP. Patients with mild symptoms monitored by pulmonary function testing, oxygenation, and chest radiography. Patient with the severity antibiotics will be given like Rituximab (Anti-CD20 monoclonal antibody)